Table 5. Multivariable linear regression models (random effects) for the expression of each target for all four time points combined.
| Ethiopia | Tanzania | ||||
|---|---|---|---|---|---|
| Target | Variable | Fold Change | P-value a | Fold Change | P-value b |
| S100A7 | Gender (female) | 1.38 | 0.049 | - | - |
| Age (years) | 1.02 | <0.0001 | 1.02 | <0.0001 | |
| Inflammation (P2/P3) | 2.28 | <0.0001 | 1.69 | 0.0009 | |
| Progressive Scarring | - | - | 1.43 | 0.027 | |
| IL1B | Gender (female) | 1.25 | 0.18 | - | - |
| Age (years) | - | - | 0.99 | 0.028 | |
| Inflammation (P2/P3) | 2.61 | <0.0001 | - | - | |
| Progressive Scarring | - | - | 1.54 | 0.0067 | |
| Il13 | Gender (female) | - | - | - | - |
| Age (years) | - | - | 0.98 | 0.0003 | |
| Inflammation (P2/P3) | - | - | - | - | |
| Progressive Scarring | 1.27 | 0.034 | - | - | |
| IL17A | Gender (female) | 1.75 | 0.0004 | - | - |
| Age (years) | - | - | 0.99 | 0.014 | |
| Inflammation (P2/P3) | 1.87 | <0.0001 | - | - | |
| Progressive Scarring | - | - | - | - | |
| CXCL5 | Gender (female) | 2.90 | 0.0001 | 1.59 | 0.0061 |
| Age (years) | 1.02 | 0.0023 | - | - | |
| Inflammation (P2/P3) | 3.20 | <0.0001 | 2.22 | <0.0001 | |
| Progressive Scarring | - | - | - | - | |
| CTGF | Gender (female) | 1.32 | 0.19 | - | - |
| Age (years) | 1.02 | 0.0007 | - | - | |
| Inflammation (P2/P3) | 3.13 | <0.0001 | 1.72 | 0.08 | |
| Progressive Scarring | - | - | - | - | |
| CEACAM5 | Gender (female) | 1.52 | 0.0002 | - | - |
| Age (years) | 1.01 | 0.010 | - | - | |
| Inflammation (P2/P3) | 1.36 | 0.0001 | 1.55 | 0.0003 | |
| Progressive Scarring | - | - | - | - | |
| MMP7 | Gender (female) | - | - | - | - |
| Age (years) | 1.01 | 0.0025 | 0.99 | 0.0006 | |
| Inflammation (P2/P3) | 1.32 | 0.085 | 1.19 | 0.048 | |
| Progressive Scarring | - | - | - | - | |
| MMP9 | Gender (female) | - | - | - | - |
| Age (years) | - | - | 0.99 | 0.023 | |
| Inflammation (P2/P3) | - | - | - | - | |
| Progressive Scarring | 0.86 | 0.050 | - | - | |
| CD83 | Gender (female) | 1.21 | 0.010 | - | - |
| Age (years) | 1.01 | 0.040 | 0.99 | 0.0008 | |
| Inflammation (P2/P3) | 1.32 | <0.0001 | - | - | |
| Progressive Scarring | - | - | 1.15 | 0.048 | |
| SPARCL1 | Gender (female) | 0.65 | 0.0002 | 1.01 | 0.022 |
| Age (years) | 0.99 | 0.016 | - | - | |
| Inflammation (P2/P3) | 0.54 | <0.0001 | 0.76 | 0.085 | |
| Progressive Scarring | - | - | - | - | |
a For the Ethiopian analysis, using the Benjamini and Hochberg approach, only tests with a p-value below 0.034 have a False Discovery Rate of <5%.
b For the Tanzanian analysis, using the Benjamini and Hochberg approach, only tests with a p-value below 0.014 have a False Discovery Rate of <5%.